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New Developments in Hyperbaric Oxygen Therapy
Abstract
Hyperbaric Oxygen Therapy, or HBOT, is a form of treatment based on the inhalation of 100% pure oxygen
while subjected to closed chamber or room at pressures greater than sea level (1 atmosphere, ATA)
(Howell et al., 2018; Kocaman, 2020). HBOT is administered through either a mono-place chamber or a
multi-place chamber. Mono-place chambers are pressurized with oxygen and are equipped to handle a
single person at a time. Multi-place chambers, on the other hand, can accommodate up to 20 people at a
time, including medical personnel and intubated patients. These chambers are pressurized with air, and
pure oxygen is administered via facemask, hood tent, or endotracheal tube (Gill & Bell, 2004; Howell et al.,
2018). Oxygen is primarily used by the body in the formation of ATP, the molecule responsible for fueling
cellular processes. When body tissues are injured or damaged, the energetic demand increases, and
consequently more oxygen is needed (Kahle & Cooper, 2020). HBOT increases the body’s arterial and
tissue oxygen tension, augmenting the amount of oxygen that the blood plasma can carry. This can
create a number of beneficial biochemical, cellular, and physiologic effects (Tibbles & Edelsberg, 1996).
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INTRODUCTION
Hyperbaric Oxygen Therapy, or HBOT, is a form of treatment based on the inhalation of
100% pure oxygen while subjected to closed chamber or room at pressures greater than sea level
(1 atmosphere, ATA) (Howell et al., 2018; Kocaman, 2020). HBOT is administered through
either a mono-place chamber or a multi-place chamber. Mono-place chambers are pressurized
with oxygen and are equipped to handle a single person at a time. Multi-place chambers, on the
other hand, can accommodate up to 20 people at a time, including medical personnel and
intubated patients. These chambers are pressurized with air, and pure oxygen is administered via
facemask, hood tent, or endotracheal tube (Gill & Bell, 2004; Howell et al., 2018). Oxygen is
primarily used by the body in the formation of ATP, the molecule responsible for fueling cellular
processes. When body tissues are injured or damaged, the energetic demand increases, and
consequently more oxygen is needed (Kahle & Cooper, 2020). HBOT increases the body’s
arterial and tissue oxygen tension, augmenting the amount of oxygen that the blood plasma can
carry. This can create a number of beneficial biochemical, cellular, and physiologic effects
(Tibbles & Edelsberg, 1996).
The first documented use of Hyperbaric Therapy occurred in 1662, even before oxygen
was discovered, when a British physician created an airtight container, called a ‘domicilium’, in
which the pressure could be altered using bellows and valves (Carden, 2020; Gill & Bell, 2004).
It was not until 1872 that this process was scientifically explained by Paul Bert, who wrote about
the physiological effects of oxygen under increased pressure which granted him the title of ‘the
Father of Hyperbaric Medicine’ (Carden, 2020; Gill & Bell, 2004). After this point, physicians
and scientists began to explore the use of HBOT to treat a variety of diseases and conditions,
including diabetes, arthritis, syphilis, and carbon monoxide intoxication, despite the lack of
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empirical evidence supporting its efficacy (Carden, 2020; Kocaman, 2020). Since then, however,
extensive research on the use of hyperbaric oxygen has been performed, especially by the United
States Naval Academy in the context of deep-sea diving and the treatment of decompression
sickness (Behnke, 1945; Carden, 2020)
PHYSIOLOGY
As noted previously, Hyperbaric Oxygen Therapy uses pure oxygen at high pressure in a
closed environment to treat numerous pathologies. The primary effect of HBOT is hyperoxia
while the secondary effects are the result of controlled oxidative stress (Choudhury, 2018). These
phenomena, in principle, are governed by the Gas Laws (Choudhury, 2018; Kocaman, 2020;
Leach, 1998; Tibbles & Edelsberg, 1996).
Dalton’s law states that in a mixture of gases, the sum of the partial pressures of the gases
will equal the total pressure in the system (Cosgrove & Bryson, 2001; Choudhury, 2018; Gill &
Bell, 2004).
Henry’s law states that at a constant temperature, the amount of gas that dissolves in a
given type and volume of liquid is directly proportional to the partial pressure of that gas in
equilibrium with that liquid (Cosgrove & Bryson, 2001; Choudhury, 2018; Kocaman, 2020).
Primary Effects
Oxygen is transferred to cells via plasma, and the initial diffusion of oxygen into the
plasma can be understood by the application of Dalton’s Law and Henry’s Law (Cosgrove &
Bryson, 2001; Choudhury, 2018). Air is composed of approximately 21% oxygen and 79%
nitrogen (Cosgrove & Bryson, 2001). The consequence of Dalton’s Law is that the partial
pressure of oxygen in the air is solely based on the percentage of oxygen in the atmosphere and
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the ambient pressure, which may vary based on altitude and other factors (Choudhury, 2018).
The partial pressure of oxygen (PaO2) in air at sea level (1 ATA = 760 mmHg) is calculated as
160 mmHg (Cosgrove & Bryson, 2001). Air in the trachea, however, has a similar partial
pressure to humidified water (47 mmHg); thus, a more appropriate calculation of inspired
oxygen at sea level would result in a PaO2 of 150 mmHg. Deoxygenated blood entering the lung
contains a PaO2 of 40 mmHg. After the diffusion of oxygen from the environment to the lungs,
the final PaO2 in the blood is 100 mmHg (Choudhury, 2018) and 50 mm Hg in the tissues (Gill
& Bell, 2004). These PaO2 values are dependent on the gradient between the partial pressure
present in the alveoli and in the deoxygenated blood (Choudhury, 2018). Therefore, a larger
difference in these two partial pressures produces greater oxygen diffusion from the alveoli into
the plasma (Tibbles & Edelsburg, 1996). Henry’s law can be used to determine how much
oxygen is dissolved in plasma. According to calculations using the O2 solubility coefficient, the
PaO2 in the blood and tissues at normobaric conditions allows for the maximum delivery of 0.3
mL oxygen per deciliter of blood (Choudhury, 2018; Tibbles & Edelsburg, 1996) but tissues
require 5-6 mL O2/dL of blood for homeostasis (Choudhury, 2018). Hemoglobin makes up for
this difference; in fact, most oxygen carried in the blood is bound to hemoglobin (Gill & Bell,
2004).
Hyperbaric Oxygen Therapy takes advantage of both Dalton’s law and Henry’s law to
increase the alveoli-plasma gradient and solubility of oxygen, respectively. To portray this
numerically, administering 100% oxygen at 3 ATA increases arterial oxygen tension to 2000
mmHg and tissue oxygen tension to 500 mmHg, allowing the delivery of 6 mL O2/dL (Gill &
Bell, 2004). Evidently, following HBOT, the dissolved oxygen carried by the plasma is sufficient
in maintaining homeostatic conditions without a contribution from hemoglobin (Kocaman,
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2020). As a result, this oxygen can be carried to tissues even with impaired hemoglobin oxygen
carriage, such as the case in carbon monoxide poisoning and severe anemia. The other advantage
of using plasma to distribute oxygen rather than hemoglobin is that with plasma, oxygen can
reach physically obstructed areas (like clots or occlusions) where red blood cells cannot pass
(Gill & Bell, 2004).
Secondary Effects
The primary effects of HBOT include correcting the hypoxic state by increasing oxygen
delivery and tension, but it is important to note that the application of HBOT to treat many
diseases derives from the secondary effects of hyperoxia at pressure (Choudhury, 2018). The
secondary, or indirect effects of HBOT, include the increase of the generation of oxygen free
radicals (ROS), the increase in the body’s healing ability & immunity, vasoconstriction,
angiogenesis, and the decrease in edema (Sureda et al., 2016; Choudhury, 2018; Kahle &
Cooper, 2020). These effects will be specifically addressed in relation to their clinical
application(s) in the following pages.
THERAPEUTIC APPLICATIONS
Decompression Illness
Decompression illness denotes two pathological syndromes—arterial gas embolism
(AGE) and decompression sickness (DCS)—that are caused by intravascular bubbles formed as a
result of a reduction in environmental pressure (Vann et al., 2011). Another gas law, Boyle’s
law, explains the root of these syndromes as well as the beneficial effects of HBOT for treating
them. Boyle’s law states that at a constant temperature, the volume of gas in an enclosed space is
proportional to the pressure exerted on it (Tibbles & Edelsburg, 1996; Gill & Bell, 2004).
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Arterial gas embolism and decompression sickness have historically been associated with
recreational diving (Diaconu et al., 2018). As a diver descends in the water column, the
increasing barometric pressure has two major effects. The first is mechanical: in the context of
Boyle’s law, the volume of any gas-containing space in the body is reduced. Thus, if one starts
off with X volume in the lungs on the surface and breaths to a depth without breathing any
additional gas, X will be halved (X/2). If one breathes from a gas source while at that depth, the
lungs will return to X. Should the diver then swim back to the surface, the X will double (2X).
This enlarging volume of gas is typically exhaled, but in cases that it is not (such as breath
holding or rapid ascent) then mechanical forces can result in disruption of lung tissue, causing
pulmonary overinflation (Vann et al., 2011; Hamm, 2019; Neuman, 2002). An example of a
pulmonary overinflation syndrome is AGE. In this condition, expanding gas ruptures alveoli
capillaries (pulmonary barotrauma) and is forced into the pulmonary vasculature and arterial
circulation (Neuman, 2002; Vann et al., 2011). Aside from diving injury, arterial gas embolism
may be caused by a number of iatrogenic reasons including mechanical ventilation, central line
placement, and hemodialysis (Kocaman, 2020; Gill & Bell, 2004). In non-fatal cases, air bubbles
partially block circulation. The clinical picture is aggravated, however, when platelets,
leukocytes, fibrinogen, and thrombin adhere to the bubble, initiating the thrombotic process and
causing deterioration of the vessel (Kocaman, 2020). These situations are manifested in the
clinical effects, which range from muscle and joint pain to more life-threatening problems like
Acute Respiratory Distress Syndrome (ARDS), brain edema, lack of brain metabolism, and
sudden death (Kocaman, 2020; Gill & Bell, 2004; Vann et al., 2011).
The second category of physiological problems associated with decompression is based
on Dalton’s law and Henry’s law (see page 3) (Choudhury, 2018). As a diver descends, the
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partial pressures of the gases they breathe is increased, which is reflected in alveolar gas and
arterial blood. Eventually, increasing amounts of gas are driven into solution in the body tissues.
When using air as a breathing medium, nitrogen gas is driven into solution. Depending on the
amount of gas driven into solution, a varying number of bubbles will form during decompression
due to the reduction in ambient pressure (Vann et al., 2011; Neuman, 2002). This gas phase
causes the signs and symptoms that are collectively referred to as DCS. Like AGE, these run on
a spectrum from rash to extreme joint pain (‘the bends’) paralysis, seizures, and even death as a
result of the blocking of lymphatics, veins, and arteries by the gas bubbles (Tibbles & Edelsburg,
1996; Vann et al., 2011; Hamm, 2019; Neuman, 2020).
HBOT is widely accepted as the only treatment for decompression sickness and arterial
gas embolism (Vann et al., 2011; Kocaman, 2020). During pressurization, also known as the
compression phase of HBOT, a contraction occurs in the gas-containing cavities of the body (as
predicted by Boyle’s law), which helps to decrease the air bubbles and relieve the pressure
present in the tissue and intravascular area (Kocaman, 2020; Tibbles & Edelsburg, 1996; Gill &
Bell, 2004). Additionally, hyperbaric oxygen hastens the dissolution of the inert gas bubble by
replacing the inert gas with oxygen, which is then rapidly metabolized by the tissues. It can also
serve to oxygenate compromised tissues and ameliorate the inflammatory responses that
contribute to tissue injury (Vann et al., 2011). In one case, administering 100% oxygen at 2.8
ATA reduced bubble volume by almost two thirds (Tibbles & Edelsburg, 1996).
Carbon Monoxide Poisoning
Carbon monoxide poisoning is the most common cause of death by poisoning in the
United States (Tibbles & Edelsburg, 1996). Upon inhalation, CO binds to hemoglobin due to its
high affinity as a gas, creating reduced arterial oxygenation and hypoxia within the cell at the
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mitochondrial level (Kocaman, 2020; Gill & Bell, 2004). This creates a number of symptoms
from dizziness and headache to seizures, dysrhythmias, and coma. CO also binds to cytochromec oxidase and myoglobin, causing delayed neurological symptoms including cognitive deficits,
cortical blindness, and psychosis (Gill & Bell, 2004). The primary effects of HBOT can be
observed in its use to effectively treat CO poisoning (Choudhury, 2018). HBOT speeds up the
separation of CO gas from hemoglobin, shortening the time it takes to be excreted from the body
and correcting intracellular hypoxia (Kocaman, 2020). While breathing room air, this process
takes 300 minutes, but with HBOT the time is shortened to 32 minutes. Additionally, HBOT
restores cytochrome-c oxidase and myoglobin, which helps to prevent the delayed neurologic
sequelae (Latham, 2020). Studies describe mixed conclusions about the use of HBOT for CO
poisoning. In one severe case of CO poisoning, HBOT preserved cognitive function but lesions
in peripheral nerves persisted, which suggests partial resolution of neurological dysfunction via
HBOT (Sinkovi et al., 2006). Another recent study suggested performing HBOT within 22 hours
after poisoning to fully prevent delayed neurological sequelae (Liao et al., 2018). More studies
are needed to confirm the optimal timing for commencing HBOT in patients with CO poisoning.
Chronic Wounds
Normal wound healing is a positive feedback system that proceeds through stages of
hemostasis, removal of infectious agents, resolution of the inflammatory response,
reestablishment of a connective tissue matrix, angiogenesis, and resurfacing (Tal et al., 2017).
Chronic wounds are those which do not proceed completely through this process due to an
intrinsic or extrinsic problem occurring in one or more of the healing phases (Kocaman, 2020;
Latham, 2020). These include diabetic wounds, venous stasis ulcers, arterial ulcers, and pressure
ulcers (Latham, 2020). Infection and ischemia are the most common causes of wound healing
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delay with hypoxia as their defining feature (Kocaman, 2020). The infection causes an
exaggerated response in the inflammatory phase of wound healing, resulting in rapid depletion of
oxygen in the tissue and insufficient blood flow as a result of edema. Ischemia occurs when the
tissue lacks oxygen, causing a delay in cellular activity and consequential interruption the
healing process (Kocaman, 2020; Gill & Bell, 2004).
Hyperbaric Oxygen Therapy helps to restore the healing process by increasing the
amount of oxygen in the blood and providing a favorable gradient for the diffusion of oxygen
into the affected tissues (Kocaman, 2020; Sureda et al., 2016). Adequate oxygen is essential to
healing since fibroblast proliferation, collagen synthesis, angiogenesis, and infection resistance
are oxygen-dependent processes (Latham, 2020; Sureda et al., 2016). HBOT has also been
shown to modulate the inflammatory process through the production of reactive oxygen species
(ROS) (Kocaman, 2020; Sureda et al., 2016). In large amounts, ROS production is detrimental
for cells; however, a moderate increase can be beneficial since they act as cellular messengers in
many signal transduction pathways. In this case, vascular endothelial growth factor (VEGF) and
endothelial-1, key promoters of the angiogenic process and myofibroblast differentiation, are
upregulated via ROS production which in turn advances chronic wound healing (Thom, 2009;
Sureda et al., 2016). In a study performed by Nguyen et al. on diabetic mice, treatment with
hyperbaric oxygen was shown to increase ROS and accelerate wound healing compared to
untreated mice, with more completed and extended reepithelization (2020).
POTENTIAL NEW INDICATIONS
Alzheimer’s Disease
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The prevalence of age-related disorders is on the rise as a result of the increase in life
expectancy. For example, Alzheimer’s Disease (AD) is the most common cause of dementia in
older adults and is ranked as the sixth leading cause of death in the United States. Despite its
predominance, however, there is presently no cure for this disease and no effective treatment to
slow progression (Shapira et al., 2018; Louisiana State University, 2019). HBOT is currently
being examined as an alternative treatment for AD, as it has been shown to improve neurological
functions and life quality in other similar incidents such as stroke and traumatic brain injury. AD
is characterized by senile plaques formed by deposits of beta-amyloid and neurofibrillary
tangles, which ultimately lead to loss of synapses and degeneration of neurons (Shapira et al.,
2018). Recent evidence suggests that hypoxia in the brain tissue plays a major role in AD
pathogenesis as a result of reduced cerebral perfusion pressure that promotes the acceleration of
beta-amyloid deposition. As a result, hyperoxic conditions have the potential to increase cerebral
perfusion, slow beta-amyloid deposition, and boost brain function (Louisiana State University,
2019). In 2019, Harch et al. demonstrated the largest improvement in brain metabolism of any
therapy for Alzheimer’s disease through the use of HBOT. After undergoing 40 HBOT
treatments, the patient reported increased memory and concentration, sleep, conversation,
appetite, resolved anxiety, and decreased disorientation (Harch et al., 2019).
Gastrointestinal Diseases
Ulcerative colitis (UC) and Chron’s disease (CD) are characterized by chronic mucosal
ulcers and increased frequency of bowel movements, often accompanied with lower
gastrointestinal bleeding (Latham, 2020). Treatment options for these patients are limited and
often invasive (Landsdorp et al., 2020). As a result of chronic inflammation, mucosal hypoxia
results, therefore, HBOT has been hypothesized as an alternative treatment option. Previous
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studies demonstrated the effectiveness of HBOT in a model of experimental colitis by decreasing
tissue damage. Although its mechanism of action is not totally clear, expression levels of
inflammatory mediators in the damaged tissue as well as neutrophil infiltration was reduced by
HBOT (Parra et al., 2020). More studies are needed to confirm the optimal number of HBOT
sessions for UC and CD patients.
COVID-19
The current COVID-19 pandemic has become an unprecedented event for healthcare
systems worldwide, with a dramatic loss of human life that continues to grow each day despite
the technological advancements that have led to a vaccine. The infectious disease is caused by
SARS-CoV-2, which causes damage to tissues and organs of the infected host by direct infection
of target cells or indirectly by prolonged activation of host defense responses (De Maio &
Hightower, 2020). Symptoms presented by an infected person can range from asymptomatic to
respiratory illness and death (Latham, 2020). Morbidity and mortality from this condition are due
to the incidence of Acute Respiratory Distress Syndrome (ARDS) which is characterized by low
arterial oxygen concentration and is likely the product of inflammation mounted by the patient’s
own response to the infection (De Maio & Hightower, 2020). Dr. Richard Levitan recently made
the striking observation that oxygen saturation levels fall to below 50% in the initial stage of
COVID-19 before the onset of respiratory symptoms. This initial stage is now being understood
as “silent hypoxia” (Levitan, 2020). This discovery may be critical in preventing respiratory
failure, and HBOT has the potential to facilitate this as soon as a reduction of arterial oxygen
concentration is detected. Currently, a COVID-19 multicenter trial is taking place to investigate
the effects of HBOT on infected patients admitted to the hospital requiring oxygen (Latham,
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2020). Hopefully, HBOT can be verified as a legitimate treatment for COVID-19 and can help to
reduce the number of lives lost as a result of the pandemic.
RISKS AND LIMITATIONS
As with any medical therapy, treatment brings both risks and benefits. The oxidative
stress that occurs as a result of high concentrations of oxygen may cause cell and tissue damage
including harm to DNA. If not adequately repaired, this can lead to mutations and therefore has
the potential to initiate cancer (Speit et al., 2002). Despite this concern, however, a review of the
scientific literature showed that the vast majority of published studies failed to demonstrate such
an effect (Feldmeier et al., 1994). Patients may experience mild-to-severe pain from rupture of
the middle ear, cranial sinuses, and (in rare cases) the teeth or lungs as a result of rapid pressure
changes (Tibbles & Edelsburg, 1996). This can be avoided by teaching the patient mitigation
strategies such as the auto inflation technique (Latham, 2020). Some limitations of HBOT exist
in the United States despite the growing list of diseases and syndromes that it can treat. In
relation to cost, HBOT is rather expensive, with an average 90-minute session costing between
$300 and $400. The cost of 30-40 sessions can therefore range from $9,000 to $16,000. An
economic analysis of hyperbaric-oxygen therapy in patients with osteoradionecrosis, however,
reported a savings of $96,000 as compared with in-hospital, nonhyperbaric-oxygen therapy
(Tibbles & Edelsburg, 1996). Next, a limited number of technical staff available makes the
installation of hyperbaric chambers difficult, as this is a heavily regulated process in the US that
requires strict adherence to manufacturer specifications (Howell, 2018). Finally, the number of
medical schools who teach hyperbaric medicine is slim. The Undersea & Hyperbaric Medical
Society (UHMS) offers fellowships at several universities for hyperbaric preventative and
emergency medicine in an effort to increase the expertise in this promising field (UHMS, 2020).
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CONCLUSION
Hyperbaric Oxygen Therapy is a branch of science that has many indications for
treatment due to its ability to counter oxygen deficits, promote healing and angiogenesis, fight
infection, and control inflammation. HBOT has been described as a “therapy in search of
diseases” (Tibbles & Edelsburg, 1996) since it is open to development and progress given the
wide range of diseases that it has been explored to treat. Evidence for its use in decompression
illness, carbon monoxide poisoning, and chronic wounds is strong, but more research is needed
for its use in Alzheimer’s disease, GI diseases, and COVID-19. Although there are risks
associated with HBOT, it is accepted as a safe procedure when administered properly. Overall,
Hyperbaric Oxygen Therapy is a relatively new treatment for the standards of contemporary
medicine. As medical technology has matured, it is the proper time to complete clarification on
the potential uses of HBOT. Supported research, advanced technological equipment, and funding
are necessary in order to develop HBOT as a mainstream treatment.
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